

Ref No. NLL/CS/2018- *91*

Date: 07.08.2018

1. National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block - G, Bandra Kurla Complex,  
Bandra (East), MUMBAI - 400 051.
2. BSE Limited  
Phiroze Jeejeebhoy Towers, Dalal Street,  
MUMBAI - 400 001.

**Sub: Financial Results.**

**Ref: Compliance Pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Sir's,

The Board of Directors of the Company at their meeting held today duly approved and took on record the limited reviewed Unaudited Standalone Financial results for the quarter ended June 30, 2018 which are enclosed herewith along with the Limited Review Report of the Auditors thereon.

This is for your information and record.

Thanking you,

Yours Sincerely,  
For Nectar Lifesciences Limited

*Ankita Jain*

(Ankita Jain)  
Company Secretary

Encl: a.a.

**To Whomsoever It May Concern**


We have reviewed the accompanying statement of unaudited financial results of **Nectar Lifesciences Limited** for the quarter ended **June 30, 2018** attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing obligation and Disclosure Requirements) Regulation 2015..

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, *Review of Interim financial information performed by Independent Auditors of the Entity* issued by the Institute of Chartered Accountant of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with applicable accounting standards i.e. Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with relevant information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Ashwani K. Gupta & Associates  
Chartered Accountants  
Firm Regn. No. 003803N



Name: Ashwani K. Gupta  
PARTNER  
Membership No.: 082808

Place: Panchkula  
Date: 07.08.2018

## NECTAR LIFESCIENCES LIMITED

Regd. Office: Vill. Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab 140507, CIN: L24232PB1995PLC016664

Tel. +91-17 62-30 8000, Fax +91-17 62-30 8135, Email: cs@neclife.com, Website : www.neclife.com

Statement of Standalone Unaudited Financial Results for the Quarter ended June 30, 2018 (Rs. in Lakhs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30-Jun-18	31-Mar-18	30-Jun-17	31-Mar-18
		Unaudited	Unaudited	Unaudited	Audited
I	<b>Income from Operations</b>				
	Sales	59,493.82	68,280.71	34,146.11	209,231.93
	Less: GST Recovered	6,222.80	8,894.40	-	19,240.64
	<b>Revenue From Operations</b>	<b>53,271.02</b>	<b>59,386.31</b>	<b>34,146.11</b>	<b>189,991.29</b>
	Other operating Income	2.52	10.20	4.30	45.14
II	Other Income	130.97	126.51	132.99	558.44
III	<b>Total Income (I + II)</b>	<b>53,404.51</b>	<b>59,523.02</b>	<b>34,283.40</b>	<b>190,594.87</b>
IV	<b>Expenses</b>				
	(a) Cost of Materials consumed	40,909.36	49,945.16	20,848.33	138,163.89
	(b) Purchase of Stock in Trade	322.18	467.55	331.29	1,527.31
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(749.52)	(4,168.87)	(312.02)	(3,043.22)
	(d) Excise Duty	-	69.02	2,369.13	2,438.15
	(e) Employee benefits expense	2,005.80	1,864.31	1,934.89	7,840.48
	(f) Finance costs	2,992.34	3,016.51	2,675.55	11,520.24
	(g) Depreciation and amortisation expense	1,629.31	1,616.51	1,545.83	6,430.88
	(h) Other expenses	4,777.91	6,097.69	3,723.68	19,460.56
	<b>Total Expenses (IV)</b>	<b>51,887.38</b>	<b>58,907.88</b>	<b>33,116.68</b>	<b>184,338.29</b>
V	<b>Profit/(loss) before exceptional items and tax (III- IV)</b>	<b>1,517.13</b>	<b>615.14</b>	<b>1,166.72</b>	<b>6,256.58</b>
VI	Exceptional Items	-	-	-	-
VII	<b>Profit from ordinary activities before tax (V - VI)</b>	<b>1,517.13</b>	<b>615.14</b>	<b>1,166.72</b>	<b>6,256.58</b>
VIII	<b>Tax Expense</b>	<b>196.68</b>	<b>226.08</b>	<b>127.68</b>	<b>1,041.10</b>
IX	<b>Profit (Loss) for the period from continuing operations (VII-VIII)</b>	<b>1,320.45</b>	<b>389.06</b>	<b>1,039.04</b>	<b>5,215.48</b>
	<b>Other Comprehensive Income</b>				
	<b>Items that will not be reclassified subsequently to profit or loss</b>				
	Remeasurement of the net defined benefit liability/asset (Net of Tax)	-	109.66	-	109.66
	<b>Total Other Comprehensive Income, (Net of Tax)</b>	<b>-</b>	<b>109.66</b>	<b>-</b>	<b>109.66</b>
	<b>Total Comprehensive Income for the period</b>	<b>1,320.45</b>	<b>498.72</b>	<b>1,039.04</b>	<b>5,325.14</b>
X	<b>Earnings per Share (EPS) (Equity shares of Re. 1/- each fully paid up)</b>				
	a) Basic	0.59	0.17	0.46	2.33
	b) Diluted	0.59	0.17	0.46	2.33

**Notes:**

- 1 The above financial results were reviewed by Audit Committee on August 07, 2018 and approved by the Board in its meeting held on August 07, 2018. The statutory auditors of the Company have conducted a "Limited Review" of the above standalone unaudited financial results for the quarter ended on June 30, 2018.
- 2 The company has opted to submit only standalone un-audited financial results during the financial year.
- 3 Previous year figures have been regrouped and reclassified wherever necessary to make them comparable with current period.
- 4 The company is exclusively in the pharmaceutical business segment.

**By Order of the Board of Directors  
of Nectar Lifesciences Limited**

(Dr. Dinesh Dua)

Chief Executive Officer & Director

Dated: 07-08-2018

Place: Chandigarh



(Aet) Manoj K. Gupta  
M.No - 82808